The India Nucleic Acid Isolation and Purification Market was valued at $101.93 Million in 2026 and projected to reach to $174.9 Million by 2031, representing a compound annual growth rate of 11.4%. India's nucleic acid isolation and purification market is poised for substantial growth, expanding from $101.93 million in 2026 to $174.90 million by 2031.
India's nucleic acid isolation and purification market is growing at 11.4% CAGR, significantly outpacing the global growth rate of 8.7%, driven by increased genomic research initiatives and diagnostic demand.
India's modernization of healthcare infrastructure and substantial government funding in molecular biology research are creating favorable conditions for market expansion and technology adoption.
India's emerging position as a global biopharmaceutical development center is driving demand for advanced nucleic acid isolation and purification technologies across research and manufacturing sectors.
Rising prevalence of genetic disorders and infectious diseases in India is accelerating adoption of nucleic acid-based diagnostic solutions in clinical and research laboratories.
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | CELL-FREE SAMPLES (Sample Type) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 8.7% from 2026 to 2031 |
| Largest Segment | CELLULAR SAMPLES (Sample Type) |
| Market Size Base Year | 6.37 (2026) |
| Revenue Forecast | 9.66 (2031) |
| Segments Covered | Product, Type, Method, Sample Type |
4 segment dimensions are covered across the global market.
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| SIGMA-ALDRICH CORPORATION | United States | Private Company | Analytical chemistry, labware, and materials science,Cell culture media, critical raw materials, and industrial microbiology,Molecular biology, functional genomics, and protein biology, |
| BECKMAN COULTER | United States | Private Company | Clinical diagnostics (chemistry, immunoassay, hematology, urinalysis, hemostasis),Flow cytometry and cellular analysis,Life science research tools (centrifugation, genomics, liquid handling, spectrophotometry), |
| FLUOR CORPORATION | United States | Public Company | Energy Solutions (traditional and transition EPC),Urban Solutions (AT&M, life sciences, mining, infrastructure),Mission Solutions (government, nuclear remediation, security), |
| SANOFI | France | Public Company | Vaccines (pediatric, RSV, hexavalent, travel),Immunology & Inflammation,Rare Diseases & Neurology, |
| GE HEALTHCARE | United States | Public Company | Imaging,Advanced Visualization Solutions (including Ultrasound and Image-Guided Therapies),Patient Care Solutions, |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| QIAGEN N.V. | Netherlands | Public Company | Sample technology consumables and instruments,Immune response and infectious disease diagnostics,Oncology and sexual/reproductive health assays, |
| MERCK KGAA | Germany | Public Company | Life Science,Healthcare,Electronics, |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing and related solutions),Life Sciences (research tools and genomic solutions),Diagnostics (clinical instruments, consumables, software), |
| AGILENT TECHNOLOGIES, INC. | United States | Public Company | Life Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets, |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Clinical Diagnostics,Life Science Research & Bioprocess, |
| ILLUMINA, INC. | United States | Public Company | Sequencing instruments,Sequencing consumables (reagents, flow cells, library prep),Array-based products, |
| TAKARA BIO INC. | Japan | Private Company | Genetic and cellular research reagents,PCR instruments and cellular analysis devices,In vitro diagnostics (including COVID-19), |
| REVVITY INC. | United States | Public Company | Diagnostics (prenatal, neonatal, infectious disease, immunodiagnostics),Life science reagents and assay platforms,Instruments, imaging, and detection systems, |
| BIONEER CORPORATION | South Korea | Public Company | PCR / RT-PCR and real-time PCR reagents and instruments,Molecular diagnostics kits and MDx extraction systems,Research reagents, RNAi, chemicals, buffers, and consumables, |
Sigma-Aldrich Corporation is a United States-based private company founded in 1951 that employs 9,800 people. The company specializes in providing research chemicals, biochemicals, and laboratory supplies to the scientific community.
Beckman Coulter is a United States-based private company founded in 1935 with 11,900 employees. The company manufactures and distributes laboratory instruments and diagnostic equipment.
Fluor Corporation is a United States-based public company founded in 1912 with 22,995 employees. The company provides engineering, procurement, and construction services across multiple industries.
Sanofi is a France-based public company founded in 1994 with 74,846 employees. The company is a global pharmaceutical organization engaged in the research, development, and commercialization of medicines.
GE Healthcare is a United States-based public company founded in 2022 with 54,000 employees. The company provides medical imaging, diagnostics, and healthcare IT solutions.
Thermo Fisher Scientific Inc. is a United States-based public company founded in 1956 with 125,000 employees. The company is a global leader in serving science, providing laboratory equipment, reagents, and analytical instruments.
QIAGEN N.V. is a Netherlands-based public company founded in 1984 with 5,500 employees. The company develops and manufactures molecular diagnostics and life sciences research products.
Merck KGaA is a Germany-based public company founded in 1668 with 59,077 employees. The company operates in pharmaceuticals, life sciences, and performance materials sectors.
Danaher Corporation is a United States-based public company founded in 1969 with 59,000 employees. The company operates a diversified portfolio of businesses in life sciences, diagnostics, and environmental solutions.
Agilent Technologies, Inc. is a United States-based public company founded in 1999 with 18,000 employees. The company provides laboratory instruments, software, and services for life sciences and diagnostics.
Bio-Rad Laboratories, Inc. is a United States-based public company founded in 1952 with 7,450 employees. The company manufactures and distributes life science research products and clinical diagnostics equipment.
Illumina, Inc. is a United States-based public company founded in 1998 with 8,625 employees. The company develops and manufactures DNA sequencing and genetic analysis systems.
Takara Bio Inc. is a Japan-based private company founded in 2002 with 1,779 employees. The company specializes in biotechnology products and services for research and diagnostics.
Revvity Inc. is a United States-based public company founded in 1937 with 11,000 employees. The company provides analytical instruments, software, and services for life sciences and diagnostics.
Bioneer Corporation is a South Korea-based public company founded in 1992 with 392 employees. The company develops and manufactures molecular biology reagents and diagnostic products.
India's nucleic acid isolation and purification market was valued at $101.93 million in 2026, representing significant growth potential in the Asia Pacific region.
India's market is forecasted to reach $174.90 million by 2031, reflecting an 11.4% compound annual growth rate over the five-year period.
India's 11.4% CAGR outpaces the global 8.7% rate due to expanding genomic research infrastructure, rising diagnostic demand, and India's role as a contract research manufacturing hub.
India's demand is driven by academic research institutions, diagnostic laboratories, pharmaceutical manufacturers, and contract research organizations focusing on genomic and molecular applications.
India represents a significant growth engine within Asia Pacific, with its 11.4% CAGR demonstrating faster expansion than many regional peers due to cost advantages and research capacity.
This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global nucleic acid isolation and purification market. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of leading market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with primary research inputs to arrive at the final market size.
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the global nucleic acid isolation and purification market. The secondary sources used for this study include WHO Disease Statistics (Oncology, Genetic Disorders), CMS Clinical Laboratory Improvement Amendments (CLIA) Laboratory Lists, Association of Public Health Laboratories (APHL) List, Regional Forensic Laboratories list, State Office of Chief Medical Examiner (OCME) List, Biocluster List of Members (Massbio, NC Bio, CLSA), Organization for Economic Co-operation and Development (OECD) R&D Expenditure, National Animal Health Laboratory Network (NAHLN) laboratories List, Genome Canada Membership List, Genome Canada Laboratories Network, Canada Statistics Business Enterprise R&D Statistics, EudraGMP Sites, Biodeutschland Member List, European Federation of Pharmaceutical Industries and Associations (EFPIA) R&D Spending, European Union Drugs Agency (EUDA) Network of forensic and toxicological laboratories list, EudraGMP Sites, BioIndustry Association Member List, NHS Genomics Laboratories Hub, UK Health Security Agency's Laboratories List, FranceBiotech List, China Pharmaceutical Industry Association (CPIA) Member List, China Chinese Center for Disease Control and Prevention (CDC) National Institute for Viral Disease Control and Prevention (IVDC) Laboratories, Japan Pharmaceutical Manufacturers Association (JPMA) & Japanese Bankers Association (JBA) Statistics, NIID (National Institute of Infectious Diseases) reference labs, Indian Pharmaceutical Association (IPA) and Organisation of Pharmaceutical Producers of India (OPPI) Membership List, Brazilian Association of Research-Based Pharmaceutical Industries (Interfarma), Fiocruz Genomic Network Institutes, KAUST Research and Technology Park Companies, Saudi Public Health Authority (Weqaya) National Reference Laboratory System, African Biomedical Engineering Consortium List, Africa CDC Pathogen Genomics Initiative (Africa PGI) Sequencing Laboratories; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; and trade, business, professional associations. These sources were also used to obtain key information on major players, market classification, and segmentation aligned with industry trends, regional/country-level markets, market developments, and technology perspectives.
Following an initial assessment of the global nucleic acid isolation and purification market landscape through secondary research, comprehensive primary research was undertaken. This involved conducting in-depth interviews with market experts from the demand side, including stakeholders from pharmaceutical and biotechnology firms, CROs, CMOs, and academic and research institutions. Additionally, interviews were conducted with key supply-side participants, including C-suite and senior executives, product managers, and marketing and sales leaders from prominent manufacturers, distributors, and channel partners. The research covered six major geographical regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% of the primary interviews were conducted with supply-side participants, while 30% were conducted with demand-side experts. Data collection methods included structured questionnaires, email correspondence, online surveys, personal interviews, and telephonic discussions to comprehensively understand market dynamics.

To know about the assumptions considered for the study, download the pdf brochure
Both bottom-up and top-down approaches were used to estimate and validate the total size of the global nucleic acid isolation and purification market. These methods were also widely used to estimate the sizes of various subsegments in the market. The research methodology used to estimate the market size includes the following:

After arriving at the market size from the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and obtain exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, as applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Nucleic acid isolation and purification is a set of molecular biology techniques used for the extraction of DNA and RNA for use in downstream applications, such as sequencing, cloning, and polymerase chain reaction. These downstream applications are important parts of life science research, molecular diagnostics, forensics, and genetic engineering. The report defines the Nucleic acid isolation and purification market as the supplier revenue market for kits, reagents, and instruments used for method, application, type of nucleic acid, and type of samples as described below in the inclusions and exclusions.
With the given market data, MarketsandMarkets offers customizations to meet your company's needs. The following customization options are available for this report:
Portfolio Assessment
Company Information
Geographical Analysis
Full forecast, segment splits, and company analysis for all Nucleic Acid Isolation and Purification Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report